AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A percutaneously absorbable preparation comprising sodium ~~dichlorofenac~~ diclofenac and ammonium chloride, wherein the ammonium chloride is blended at the range of from 0.5 to 10 fold mole based on the sodium diclofenac ~~dichlorofenac~~.

2. (Cancelled).

3. (Cancelled)

4. (Previously presented) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is a nonaqueous preparation.

5. (Currently Amended) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is a patch comprising a matrix, ~~-type patch~~ or an ointment.

6. (Cancelled)

7. (Currently amended) The percutaneously absorbable preparation according to claim 1, wherein the ammonium chloride is combined at the range of from 0.5 to 7 fold mole based on the sodium ~~dichlorofenac~~ diclofenac.

8. (Currently Amended) The percutaneously absorbable preparation according to any one of claims 1, 4-5 or 7, which is a ~~matrix-type~~ percutaneously absorbable matrix preparation, wherein the sodium ~~dichlorofenac~~ diclofenac and the ammonium chloride are contained in an adhesive basis layer.

9. (Currently amended) The ~~matrix-type~~ percutaneously absorbable preparation according to claim 8, wherein the adhesive basis layer is composed of one or more than two of ~~stylene~~ styrene-isoprene-styrene ~~stylene~~ block copolymer, polyisobutylene, and acrylic adhesive.

10. (Currently Amended) A percutaneous absorption accelerating composition of sodium diclofenac ~~dichlorofenac~~, which contains ammonium chloride, wherein the ammonium chloride is blended at the range of from 0.5 to 10 fold mole based on the sodium diclofenac ~~dichlorofenac~~.

11. – 12. (Cancelled)